Clinical trials: Bone Marrow Neoplasms
Multiple Myeloma
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing…
- Trial name
- NCT00431340
- Testing
- PXD101
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Valerio Therapeutics
Chronic Myeloid Leukemia
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
- Trial name
- NCT00303290
- Testing
- Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoblastic Leukemia, Cancer Survivors
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.
- Conditions
- Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes
- Trial name
- IAMFIT (NCT05194397)
- Testing
- Nicotinamide Riboside, Exercise Intervention
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Hospital of Philadelphia
Chronic Myelogenous Leukemia, CML Chronic Phase
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation.
- Conditions
- Chronic Myelogenous Leukemia, CML Chronic Phase, CML Accelerated Phase
- Trial name
- NCT06530810
- Testing
- HS-10382+Flumatinib
- Volunteers
- 100 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome)
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
The goal of this clinical trial is to evaluate the effectiveness and safety of the anti-NKG2A monoclonal antibody (Monalizumab) in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation…
- Conditions
- Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms)
- Trial name
- NCT06892223
- Testing
- Monalizumab (anti-NKG2A monoclonal antibody)
- Where
- 2 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Istituto Clinico Humanitas
Chronic Myelogenous Leukemia, Multiple Myeloma
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
Primary Objectives: To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic myelomonocytic leukemia (CMML), chronic…
- Conditions
- Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease
- Trial name
- NCT00038818
- Testing
- CD8 Depleted Donor Lymphocyte
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndromes
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00030550
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
This will be a phase II, open-label, non-randomized study with a safety lead-in phase. There are 3 Arms in this study each with 2 parts. If you are eligible, you will be assigned to an Arm and a part when you join the study.
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02397720
- Testing
- Azacitidine, Ipilimumab, Venetoclax
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Haplo-Cord HSCT for AML/MDS
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze…
- Trial name
- NCT07588360
- Testing
- haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
- Where
- 4 sites in China
- Volunteers
- 82 people
- Sponsor
- Fujian Medical University Union Hospital
Leukemia, Myelodysplastic Syndromes
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00068276
- Testing
- cholecalciferol
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Chronic Myelogenous Leukemia
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became…
- Trial name
- NCT00041990
- Testing
- decitabine (5-aza-2'deoxycytidine)
- Where
- 8 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8.
- Trial name
- NCT00877110
- Testing
- cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
This is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with Acute Myeloid Leukemia (AML), or Myelodysplastic Syndromes (MDS)/AML, with either refractory or relapsed…
- Trial name
- ACHIEVE (NCT05358808)
- Testing
- TCB008
- Where
- 6 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- TC Biopharm
Polycythemia Vera, Essential Thrombocythemia
Familial Myeloproliferative Disorders
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Idiopathic Myelofibrosis
- Trial name
- NCT00666289
- Where
- 6 sites in United States, Italy
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007891
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- Cancer Research Institute of Contra Costa
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
- Trial name
- NCT03595917
- Testing
- ABL001, Dasatinib, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Marlise Luskin, MD